Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with the Risk of Hospitalization and Death in Hypertensive Patients with Coronavirus Disease-19

View ORCID ProfileRohan Khera, Callahan Clark, Yuan Lu, Yinglong Guo, Sheng Ren, Brandon Truax, View ORCID ProfileErica S Spatz, View ORCID ProfileKarthik Murugiah, View ORCID ProfileZhenqiu Lin, View ORCID ProfileSaad B Omer, View ORCID ProfileDeneen Vojta, View ORCID ProfileHarlan M Krumholz
doi: https://doi.org/10.1101/2020.05.17.20104943
Rohan Khera
1Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX
2Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rohan Khera
Callahan Clark
3Research & Development at UnitedHealth Group
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuan Lu
2Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT
4Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yinglong Guo
3Research & Development at UnitedHealth Group
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sheng Ren
3Research & Development at UnitedHealth Group
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brandon Truax
3Research & Development at UnitedHealth Group
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erica S Spatz
2Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT
4Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Erica S Spatz
Karthik Murugiah
2Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT
4Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Karthik Murugiah
Zhenqiu Lin
2Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT
4Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zhenqiu Lin
Saad B Omer
5Yale Institute for Global Health, New Haven, CT
6Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
7Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Saad B Omer
Deneen Vojta
3Research & Development at UnitedHealth Group
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Deneen Vojta
Harlan M Krumholz
2Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT
4Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
8Department of Health Policy and Management, Yale School of Public Health, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Harlan M Krumholz
  • For correspondence: harlan.krumholz@yale.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Whether angiotensin-converting enzyme (ACE) Inhibitors and angiotensin receptor blockers (ARBs) mitigate or exacerbate SARS-CoV-2 infection remains uncertain. In a national study, we evaluated the association of ACE inhibitors and ARB with coronavirus disease-19 (COVID-19) hospitalization and mortality among individuals with hypertension.

Methods Among Medicare Advantage and commercially insured individuals, we identified 2,263 people with hypertension, receiving ≥1 antihypertensive agents, and who had a positive outpatient SARS-CoV-2 test (outpatient cohort). In a propensity score-matched analysis, we determined the association of ACE inhibitors and ARBs with the risk of hospitalization for COVID-19. In a second study of 7,933 individuals with hypertension who were hospitalized with COVID-19 (inpatient cohort), we tested the association of these medications with in-hospital mortality. We stratified all our assessments by insurance groups.

Results Among individuals in the outpatient and inpatient cohorts, 31.9% and 29.8%, respectively, used ACE inhibitors and 32.3% and 28.1% used ARBs. In the outpatient study, over a median 30.0 (19.0 - 40.0) days after testing positive, 12.7% were hospitalized for COVID-19. In propensity score-matched analyses, neither ACE inhibitors (HR, 0.77 [0.53, 1.13], P = 0.18), nor ARBs (HR, 0.88 [0.61, 1.26], P = 0.48), were significantly associated with risk of hospitalization. In analyses stratified by insurance group, ACE inhibitors, but not ARBs, were associated with a significant lower risk of hospitalization in the Medicare group (HR, 0.61 [0.41, 0.93], P = 0.02), but not the commercially insured group (HR: 2.14 [0.82, 5.60], P = 0.12; P-interaction 0.09). In the inpatient study, 14.2% died, 59.5% survived to discharge, and 26.3% had an ongoing hospitalization. In propensity score-matched analyses, neither use of ACE inhibitor (0.97 [0.81, 1.16]; P = 0.74) nor ARB (1.15 [0.95, 1.38]; P = 0.15) was associated with risk of in-hospital mortality, in total or in the stratified analyses.

Conclusions The use of ACE inhibitors and ARBs was not associated with the risk of hospitalization or mortality among those infected with SARS-CoV-2. However, there was a nearly 40% lower risk of hospitalization with the use of ACE inhibitors in the Medicare population. This finding merits a clinical trial to evaluate the potential role of ACE inhibitors in reducing the risk of hospitalization among older individuals, who are at an elevated risk of adverse outcomes with the infection.

Competing Interest Statement

Dr. Krumholz was a recipient of a research grant, through Yale, from Medtronic and the United States Food and Drug Administration to develop methods for post-market surveillance of medical devices; was a recipient of a research grant with Medtronic and is the recipient of a research grant from Johnson & Johnson, through Yale University, to support clinical trial data sharing; was a recipient of a research agreement, through Yale University, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion; collaborates with the National Center for Cardiovascular Diseases in Beijing; receives payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, from the Ben C. Martin Law Firm for work related to the Cook Celect IVC filter litigation, and from the Siegfried and Jensen Law Firm for work related to Vioxx litigation; chairs a Cardiac Scientific Advisory Board for UnitedHealth; was a participant/participant representative of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Advisory Board for Facebook, and the Physician Advisory Board for Aetna; and is a co-founder of HugoHealth, a personal health information platform, and co-founder of Refactor Health, an enterprise healthcare artificial intelligence-augmented data management company. Drs. Krumholz, Lin, Spatz and Murugiah work under contract with the Centers for Medicare & Medicaid Services to develop and maintain performance measures that are publicly reported. Dr. Spatz receives support from the Food and Drug Administration to support projects within the Yale-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI); the National Institute on Minority Health and Health Disparities (U54MD010711-01) to study precision-based approaches to diagnosing and preventing hypertension; and the National Institute of Biomedical Imaging and Bioengineering (R01EB028106-01) to study a cuff-less blood pressure device. Drs. Clark, Ren, Vojta, and Mr. Guo and Mr. Truax are full-time employees in Research & Development at UnitedHealth Group and own stock in the company. The other authors report no potential conflicts of interest.

Funding Statement

The study was funded by Research & Development at UnitedHealth Group, and the authors Drs. Clark, Ren, Vojta, and Mr. Guo and Mr. Truax are full-time employees of the UnitedHealth Group. These authors played an active in all aspects of the development of the study, including design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Dr. Khera also reports support from the National Center for Advancing Translational Sciences (UL1TR001105) of the National Institutes of Health. Dr. Lu is supported by the National Heart, Lung, and Blood Institute (K12HL138037) and the Yale Center for Implementation Science. The NIH had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data are proprietary and are not available for open sharing due to restrictions on our data use agreement

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted May 19, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with the Risk of Hospitalization and Death in Hypertensive Patients with Coronavirus Disease-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with the Risk of Hospitalization and Death in Hypertensive Patients with Coronavirus Disease-19
Rohan Khera, Callahan Clark, Yuan Lu, Yinglong Guo, Sheng Ren, Brandon Truax, Erica S Spatz, Karthik Murugiah, Zhenqiu Lin, Saad B Omer, Deneen Vojta, Harlan M Krumholz
medRxiv 2020.05.17.20104943; doi: https://doi.org/10.1101/2020.05.17.20104943
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with the Risk of Hospitalization and Death in Hypertensive Patients with Coronavirus Disease-19
Rohan Khera, Callahan Clark, Yuan Lu, Yinglong Guo, Sheng Ren, Brandon Truax, Erica S Spatz, Karthik Murugiah, Zhenqiu Lin, Saad B Omer, Deneen Vojta, Harlan M Krumholz
medRxiv 2020.05.17.20104943; doi: https://doi.org/10.1101/2020.05.17.20104943

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (51)
  • Cardiovascular Medicine (453)
  • Dentistry and Oral Medicine (83)
  • Dermatology (55)
  • Emergency Medicine (158)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (191)
  • Epidemiology (5273)
  • Forensic Medicine (3)
  • Gastroenterology (196)
  • Genetic and Genomic Medicine (759)
  • Geriatric Medicine (80)
  • Health Economics (213)
  • Health Informatics (700)
  • Health Policy (361)
  • Health Systems and Quality Improvement (224)
  • Hematology (99)
  • HIV/AIDS (164)
  • Infectious Diseases (except HIV/AIDS) (5895)
  • Intensive Care and Critical Care Medicine (363)
  • Medical Education (105)
  • Medical Ethics (25)
  • Nephrology (83)
  • Neurology (767)
  • Nursing (43)
  • Nutrition (131)
  • Obstetrics and Gynecology (144)
  • Occupational and Environmental Health (234)
  • Oncology (480)
  • Ophthalmology (152)
  • Orthopedics (39)
  • Otolaryngology (95)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (141)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (99)
  • Psychiatry and Clinical Psychology (865)
  • Public and Global Health (2023)
  • Radiology and Imaging (349)
  • Rehabilitation Medicine and Physical Therapy (158)
  • Respiratory Medicine (287)
  • Rheumatology (94)
  • Sexual and Reproductive Health (74)
  • Sports Medicine (77)
  • Surgery (110)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)